Serina Therapeutics announced that its Parkinson's drug candidate SER-252 has progressed to Cohort 2 in its registrational study after a positive safety review. Dosing in this higher dose cohort has begun, aiming to improve symptom control in advanced Parkinson's patients. Initial data from Cohort 1 showed sustained drug exposure and motor function improvements, supporting further development. Topline results from the ongoing single-ascending-dose study are expected in the first half of 2027.
Serina Therapeutics' Parkinson's drug candidate progress is noted alongside Health-sector market activity on Pluang as of Nov 13, 2026 04:11 WIB. Of 150 priced Health-sector US stocks, 23 rose and 124 fell today. Notable movers include IBRX at USD 6.06 with a 1-day change of -9.15% and Pluang order activity of 98% Sell, BNGO at USD 1.00 down 9.09% with balanced order activity, and FLNA at USD 0.44 down 8.71% with strong buy interest and a typical hold time of 39 days.
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
